3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
lutetium Lu 177 dotatate
14
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Everolimus
8
cabozantinib
6
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
X-Rays
3
Lutetium-177
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
Sunitinib
2
Phantoms, Imaging
2
Octreotide
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AMG 757
×
NET
×
90 days
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts